69 results about "Anorectic" patented technology

The present invention provides therapeutic formulations for solutions of DELTA9-tetrahydrocannabinol (DELTA9 THC) to be delivered by metered dose inhalers. The formulations, which use non-CFC propellants, provide a stable aerosol-deliverable source of DELTA9 THC for the treatment of various medical conditions, such as: nausea and vomiting associated with chemotherapy-muscle spasticity; pain; anorexia associated with AIDS wasting syndrome, epilepsy; glaucoma; bronchial asthma; and mood disorders.

The present invention relates to an anorectic containing a compound having a DGAT inhibitory activity (DGAT1 inhibitory activity) or a prodrug thereof or a pharmaceutically acceptable salt thereof as an active ingredient. The present invention provides an anti-obesity drug which is an anorectic that does not directly act on the central nervous system and is satisfactory in terms of activity, and a therapeutic strategy for preventing or treating obesity.

The invention discloses an edible traditional Chinese medicine composition and a preparation method thereof. The edible traditional Chinese medicine composition is prepared from 6 to 30 parts by weight of white hyacinth bean, 6 to 30 parts by weight of dioscorea rhizome, 6 to 30 parts by weight of white poria, 6 to 30 parts by weight of coix seed, 6 to 30 parts by weight of semen nelumbinis, 6 to 30 parts by weight of gordon euryale seed, 3 to 15 parts by weight of dried ginger, 4 to 20 parts by weight of haw, 4 to 20 parts by weight of germinated barley, 3 to 15 parts by weight of inner membrane of chicken gizzard, and 3 to 15 parts by weight of orange peel. The edible traditional Chinese medicine composition has functions of invigorating spleen and tonifying qi, excreting dampness and stopping diarrhea, warming the middle warmer and promoting appetite, improving intestinal immunity, adjusting intestinal functions and promoting digestion. The edible traditional Chinese medicine composition is mainly used for treating children's diarrhoea caused by spleen deficiency, anorexia, dyspepsia and drug-induced diarrhea. The edible traditional Chinese medicine composition has mild properties and flavor, can be used as a medicine and a food, and has no toxic and side effects, a sweet smell, an excellent taste and a wide application range.

The present disclosure relates, in one aspect, to use of ghrelin splice variant or an analogue thereof for the preparation of a medicament for one or more of: treatment and / or prevention of loss of body weight and body fat, prophylaxis or treatment of cachexia, stimulation of appetite, stimulation of food intake, stimulation of weight gain, or increasing body fat mass, or increasing body lean mass. Another aspect relates to the use of a ghrelin splice variant-like compound for the preparation of a medicament for the prophylaxis or treatment of cancer cachexia in an individual in need of such treatment. Another aspect relates to the use of a ghrelin splice variant-like compound for the preparation of a medicament for prophylaxis or treatment of cachexia in an individual by administering a subcutaneous dosage of said medicament to the individual. A further aspect relates to the use of a ghrelin splice variant-like compound or a pharmaceutically acceptable salt thereof for the preparation of a medicament for stimulation of appetite in an individual by administering a subcutaneous dosage of said medicament to the individual. A further aspect relates to a number of new ghrelin splice variant-like compounds and uses thereof, as well as to pharmaceutical compositions and medical packaging comprising the new ghrelin splice variant-like compounds.

A pharmaceutical composition which comprises an insulin sensitizer in combination with an anorectic, which is useful as an agent for preventing or treating diabetes.

A method of treatment using pharmaceutical compositions containing novel antagonists or inverse agonists at opioid receptors for the treatment of binge eating disorder, anorexia nervosa, bulimia nervosa, excess drug or alcohol use, or eating disorder not otherwise specified.

The invention provides a Chinese medicinal composition for improving appetite and promoting digestion. The Chinese medicinal composition is prepared from the following medicinal raw materials: fried magnolia officinalis, costus root, fried bitter orange, fried medicated leaven, tangerine peel, hawthorn, radish seed, saruma henryi and atratylodes rhizome. The Chinese medicinal composition can be used for treating fullness and distention of the chest and abdomen, accumulation of food in the stomach and intestine due to indigestion, vomiting, diarrhoea, abdominal pain, anorexia and the like. Theinvention also provides a physicochemical identification method for the medicinal composition.

The present invention relates to compounds of general formula Iwherein the groups and radicals B, k, L, U, V, W, X, Y, Z, R1, R2, have the meanings given in claim 1. Moreover the invention relates to pharmaceutical compositions containing at least one compound according to the invention. By virtue of their MCH-receptor antagonistic activity the pharmaceutical compositions according to the invention are suitable for the treatment of metabolic disorders and / or eating disorders, particularly obesity, bulimia, anorexia, hyperphagia and diabetes.

The invention provides a method for producing an orexin neuron by culturing a pluripotent stem cell or a neural progenitor cell in the presence of N-acetyl-D-mannosamine and optionally in the presence of at least one inhibitor selected from the group consisting of a Sirtuin 1 inhibitor and an O-linked β-N-acetylglucosamine transferase inhibitor. The invention also provides a therapeutic agent for narcolepsy or eating disorders, such as anorexia, containing N-acetyl-D-mannosamine, which is based on the induction of orexin neuron in vivo.

The invention relates to an appetizing chewing tablet. The appetizing chewing tablet is prepared through using the following raw materials, by weight, 100-160 parts of a concentrate, 10-20 parts of haw powder, 30-50 parts of zinc gluconate, 3-5 parts of sorbitol, 1-3 parts of xylitol, 10-30 parts of maltodextrin, and 1-2 parts of magnesium stearate; and the raw drugs of the concentrate comprise the following drug materials, by weight, 55-85 parts of haw, 8-12 parts of malt, 9-11 parts of Radish Seed, 4-6 parts of white hyacinth bean, 10-20 parts of Chinese yam, 3-7 parts of dried orange peel and 350 parts of water. The appetizing chewing tablet has substantial food digestion, stomach strengthening, qi rectifying, spleen invigorating and appetite promoting efficacies, and can prevent the anorexia; the preparation technology has the advantages of simplicity and high efficiency; and the appetizing chewing tablet has the advantages of simple storage, convenient carrying and administration, good taste, and suitableness for the wide popularization and application.

The present invention relates to compounds of general formula Iwherein the groups and radicals B, k, L, U, V, W, X, Y, Z, R1, R2, have the meanings given in claim 1. Moreover the invention relates to pharmaceutical compositions containing at least one compound according to the invention. By virtue of their MCH-receptor antagonistic activity the pharmaceutical compositions according to the invention are suitable for the treatment of metabolic disorders and / or eating disorders, particularly obesity, bulimia, anorexia, hyperphagia and diabetes.

The present invention relates to novel compounds of formula (I) useful as MCH receptor antagonists. These compounds are useful in pharmaceutical compositions for the prevention or therapeutic improvement of memory dysfunction, sleep and wakefulness disorders, anxiety, depression, mood disorders, seizures, obesity, diabetes, appetite and food intake Abnormalities, cardiovascular disease, hypertension, dyslipidemia, myocardial infarction, binge eating disorder (including bulimia), anorexia, psychosis (including manic depression), schizophrenia, delirium, dementia, catatonia, cognitive impairment , attention deficit disorder, substance use disorder, movement disorders (including Parkinson's disease), epilepsy, and addiction.

The present invention encompasses novel substituted pyrimidine compounds of Formula (I): which act as MCH receptor antagonists. These compounds are useful in pharmaceutical compositions whose use includes prophylaxis or treatment of improving memory function, sleeping and arousal, anxiety, depression, mood disorders, seizure, obesity, diabetes, appetite and eating disorders, cardiovascular disease, hypertension, dyslipidemia, myocardial infarction, binge eating disorders including bulimia, anorexia, mental disorders including manic depression, schizophrenia, delirium, dementia, stress, cognitive disorders, attention deficit disorder, substance abuse disorders and dyskinesias including Parkinson's disease, epilepsy, and addiction.

The present invention relates to novel compounds of Formula (1): which act as MCH receptor antagonists. These compositions are useful in pharmaceutical compositions whose use includes prophylaxis or treatment of improving memory function, sleeping and arousal, anxiety, depression, mood disorders, seizure, obesity, diabetes, appetite and eating disorders, cardiovascular disease, hypertension, dyslipidemia, myocardial infarction, binge eating disorders including bulimia, anorexia, mental disorders including manic depression, schizophrenia, delirium, dementia, stress, cognitive disorders, attention deficit disorder, substance abuse disorders and dyskinesias including Parkinson's disease, epilepsy, and addiction.

This invention relates to the use of a ligand of the 5-HT4 receptor or of a pharmaceutically acceptable salt of this ligand and to a nucleic acid coding for a 5-HT4 receptor or of a functionally equivalent receptor for a drug for treating and / or preventing a pathology associated with an obsessional behavior such as anorexia, bulimia and the addiction to drugs of abuse or obesity. The invention also relates to a method for identifying a compound that is biologically active in the treatment and / or the prevention of a pathology associated with an obsessional conduct or obesity including: a) placing the 5-HT4 receptor or a functionally equivalent receptor in contact with this biologically active compound, and b) the determination of whether this biologically active compound is capable of modulating the basal activity of the 5-HT4 receptor or of a functionally equivalent receptor.

The invention discloses a traditional Chinese medicine for acupoint application to treat child anorexia. The traditional Chinese medicine comprises the following components in parts by weight: 3 parts of roasted white atractylodes rhizome, 2 parts of fructus amomi, 2 parts of amomum cardamomum, 1 part of scorched hawthorn fruit, 1 part of roasted malt and 1 part of raw gizzard lining. The principle that 'Spleen tonifying lies in movement rather than supplement' is taken as a guiding principle in treatment of the disease. The traditional Chinese medicine can be used for strengthening the spleen and harmonizing the stomach as main functions and cannot tonify too much or simply cure indigestion. The roasted roasted white atractylodes rhizome has the effects of tonifying qi and tonifying the spleen as a monarch drug; the fructus amomi and the amomum cardamomum are sweet, have the effects of refreshing the mind, warming the middle warmer and promoting circulation of qi as ministerial drugs, and help the roasted white atractylodes rhizome tonify the spleen, so that the spleen can be transformed; the scorched hawthorn fruit, the roasted malt and the raw gizzard lining have the effects of helping digestion and invigorating the stomach as adjuvant drugs, and can help the roasted white atractylodes rhizome transform water and grain. The overall formula has the effects of tonifying the spleen, warming the middle warmer and promoting circulation of qi, helping digestion and invigorating the stomach in common. Thus, the traditional Chinese medicine has the effects of strengthening the temperament, enhancing the appetite and enhancing the orexia, is flavorous in taste, and is the source of qi and blood.

The invention discloses beta-carboline derivatives with structural characteristics shown in a formula (I), and also discloses pharmaceutically acceptable salts of the beta-carboline derivatives, a preparation method of the beta-carboline derivatives and application of the beta-carboline derivatives as selective monoamine oxidase B inhibitors. The compounds of the invention are useful for the treatment of neuropsychiatric and degenerative diseases modulated by selective monoamine oxidase B inhibitors, including Parkinson's disease, Alzheimer's disease, obsessive-compulsive disorder, depression, schizophrenia, anorexia nervosa and migraine.

The present invention relates to novel substituted piperidine and piperazine derivatives as melanocortin-4 receptor (MC-4R) modulators. MC-4R agonists of the invention can be used for the treatment of disorders and diseases such as obesity, diabetes and sexual dysfunction, whereas the MC-4R antagonists are useful for the treatment of disorders and diseases such as cancer cachexia, muscle wasting, anorexia, anxiety and depression. All diseases and disorders, where the regulation of the MC-4R is involved, can be treated with the compounds of the invention.

The present invention relates to methods of treating obesity, anorexia nervosa, or bulimia nervosa comprising administering a compound of the invention. The present invention further relates to the treatment of metabolic syndrome comprising administering a compound of the invention.

A Chinese medicine in the form of particles for treating baby anorexia, loss of appetite, nausea, etc is prepared from 7 Chinese-medicinal materials including magnolia bark, tangerine peel, rhubarb, liquorice root, etc. Its preparing process is also disclosed.

The invention relates to a medicinal composition for treating infantile anorexia and a preparation method thereof, and belongs to the field of traditional Chinese medicines. The infantile anorexia relates to a disease that children dislike eating food, has no appetite and even refuse to eat food. Children with the infantile anorexia have no active desire to eat and hate eating food. The disease is more common in children aged 1-6 years and is more common in urban children. Patients, who are not cured for a long time or receive no treatment or receive wrong treatment, may develop chronic nutritional disorders. Main causes of the infantile anorexia are improper diet, improper nursing, breast milk lack, dependence on milk powder nursing, and late addition of complementary food in babyhood. The infantile anorexia can be caused by factors that children have tender viscera and can be easily affected by exogenous pathogenic factors; children cannot control diet, and spleens and stomachs of children can be easily injured; and spleens and stomachs of children who take chemical medicines too much or too often when the children are ill can be injured. Treatment principles for the disease are to tonify the spleen and the stomach and enhance digestive and absorption abilities, and measures of warming spleen and stomach and resolving dampness, conditioning qi function and benefiting digestion, and nourishing stomach and yin can be taken as supplementary, thereby achieving effects of treating the infantile anorexia, increasing appetite and improving physical health.

Disclosed is an aminopyrrolidine compound represented by the formula [I] or a pharmaceutically acceptable salt thereof. The compound or the salt is useful as a prophylactic / therapeutic agent for mode disorder such as depression, anxiety disorder, anorexia, cachexia, pain and drug dependence, whose action relies on the MC4 receptor antagonistic effect.

The invention pertains to the traditional Chinese medicine field, which provides a medicine used for curing anorexia and limosis and is produced by the following raw medicines with portions by weight: 9-10 portions of corn, 9-10 portions of yam, 3-4 portions of corium stomachichum galli, 3-4 portions of atractylodes rhizome, 2-3 portions of monascus, 0.5-1 portions of rhubarb and 2-3 portions of black soybeans. The medicine of the invention gathers the health preserving and hygiene, treatment and rehabilitation in integral whole, promotes stomach reception, splenic normal functioning and intestinal absorption, and can achieve the aims of effectively curing the anorexia and the limosis through opsonizing human intestinal flora.

This application relates to methods of diagnosing and treating anorexia nervosa (AN) and binge eating disorder (BED) with a nonselective activator of metabotropic glutamate receptors (mGluRs).

Composition (I) comprises: dried molasses; and live, dehydrated and encapsulated microorganisms. An independent claim is included for preparing the composition comprising mixing the molasses with the live, dehydrated and encapsulated microorganisms; and drying. ACTIVITY : Anabolic; Anorectic; Tranquilizer; Muscular-Gen.; Neuroprotective; Immunomodulator; Antimicrobial; Fungicide; Laxative; Antiinflammatory; Gastrointestinal-Gen.; Antidiabetic; Antilipemic; Antiarteriosclerotic; Metabolic; Immunostimulant; Osteopathic; Antiarthritic. MECHANISM OF ACTION : None given.

Pharmaceutical formulations and methods useful for the treatment of anorexia and the stimulation of appetite and weight gain, and the management of weight loss in dogs and cats.

The invention relates to a drug for treating infantile anorexia, which is a powder product prepared by evenly mixing bitter orange, pinellia tuber and liquoric root after concoction with Chinese thorowax root, baical skullcap root, pilose asiabell root, cuttlebone, chicken's gizzard-membrane, ginger and Chinese date, adding water for decoction, then concentrating into a thick paste, drying, smashing, packaging into a bag, and carrying out sterilization and disinfection. The drug has the effects of dispersing stagnated liver, promoting bile flow, strengthening spleen, regulating stomach, promoting digestion and removing food stagnation and is characterized by actual efficacy, rapidness, convenience and safe administration for treating the infantile anorexia. The clinical observation shows that the effective rate of the drug is 98.0%.

The invention provides compounds of the Formula:that are useful for the treatment of depression (including but not limited to major depressive disorder, childhood depression and dysthymia), anxiety, panic disorder, post-traumatic stress disorder, premenstrual dysphoric disorder (also known as pre-menstrual syndrome), attention deficit disorder (with and without hyperactivity), obsessive compulsive disorder, social anxiety disorder, generalized anxiety disorder, obesity, eating disorders such as anorexia nervosa, bulimia nervosa, vasomotor flushing, cocaine and alcohol addiction, sexual dysfunction and related illnesses.

The invention provides a Chinese medicinal composition treating anorexia. The Chinese medicinal composition is prepared from hawthorns, astragalus, poria cocos, tangerine peels, tsaoko amomum fruits, fructus lycii, fructus oryzae and hordei germinatus, Alpinia officinarum Hance, Nardostachys chinensis, and radish seeds in certain mass ratio. The invention has the obvious advantages that it makes use of the combined actions of all Chinese medicines to treat anorexia, not only can makes patients restore their appetites in a short term, but also has no side effect, and meanwhile has a low price.